The revenue of the cell-based assays market in 2017 is estimated at $13bn and is expected to grow at a CAGR of 9.2% in the first half of the forecast period. Visiongain estimated that the consumables and services segments accounted for 74.26% of the market.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 241-page report you will receive 85 tables and 103 figures– all unavailable elsewhere.
The 241-page report provides clear detailed insight into the cell-based assays market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Cell-based Assays market forecasts from 2018-2028
• This report provides individual revenue forecasts to 2028 for these national markets: • US • Japan • Germany • UK • France • Spain • Italy • China • India • Russia • Brazil
• Our study includes SWOT and STEP analysis of the cell-based assays market.
• Our study discusses the selected leading companies that are the major players in the cell-based assays market: • BD (Becton, Dickinson and Company) • BioAgilytix Labs • BioVision • Cell Assay Innovations, Inc. • Charles River Laboratories International • CYTOO SA • DiscoverX • GE Healthcare • InSphero • Marin Biological Laboratories • Molecular Devices • Perkin Elmer • Pharmaceutical Product Development • Porsolt • Promega • ProQinase GmbH • QGel • SGS Group, Inc. • Thermo Fisher Scientific (and Affymetrix acquisition)
• This report also discusses technology, trends and future outlook of the cell-based assays industry
Visiongain’s study is intended for anyone requiring commercial analyses for the cell-based assays market. You find data, trends and predictions.
Buy our report today Cell-Based Assays World Industry and Market 2018-2028: Drug Discovery, Basic Research, Predictive Technology, Instrument, Consumables, Software, Services, Reagents, Assay Kits, Microplates, Cell Lines, Probes & Labels, Pharma & Biotech Companies, Academic Institutes, CROs.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Cell-Based Assays Overview 1.2 Cell-Based Assays Market Segmentation 1.3 Why You Should Read This Report 1.4 How This Report Delivers 1.5 Questions Answered by this Report 1.6 Who is this Report for? 1.7 Research Methods and Analysis 1.8 Frequently Asked Questions 1.9 Associated Reports 1.10 About Visiongain
2. Introduction to Cell-Based Assays and Applications 2.1 Cost of New Drug Discovery and Development Reaches $2.6bn – Companies Constantly Looking for Increased Efficiencies 2.2 Drug Discovery Approaches – Target-Based and Phenotype-Based Discovery 2.3 Drug Screening Assays 2.4 Animal Models Present In Vivo Conditions: But Do Results Translate to Humans? 2.5 Biochemical Assays and their Advantages over Animal Models 2.5.1 Applications of Biochemical Assays 2.5.2 Lead Identification and Toxicity Testing 2.6 Cell-Based Assays and their Advantages 2.7 2D vs 3D Cell-Based Assays 2.8 Advanced Cell-Based Assays 2.9 The Different Assay Detection Methods and Technologies 2.10 Cells used in Cell-Based Assays 2.10.1 Immortalised Cell Lines – Convenient but not Truly Representative of Normal Human Cell Lines 2.10.2 Primary Cells: Closer to the In Vivo Environment 2.10.3 Stem Cells: Potential to Overcome Limitations of Primary cells and Immortalised Cell Lines 2.11 Uses for Cell-Based Assays in Drug Discovery and Development 2.11.1 Target Validation 2.11.2 Primary Screening 2.11.3 Secondary Screening 2.11.4 ADME Screening 2.11.5 High Throughput Screening: Greatly Increases Efficiency 3. World Cell-Based Assays Market 2018-2028 3.1 Global Cell-Based Assays Market Forecast 2018-2028 3.2 Drivers for the Cell-Based Assays Market 3.2.1 Growing incidence of chronic diseases 3.2.2 Increasing R&D investment in drug discovery research 3.2.3 Growing adoption of high-throughput screening methodologies 3.2.4 Rapid technological advancements 3.3 Restraints for the Cell-Based Assays Market 3.3.1 High cost of instruments 3.3.2 Dearth of skilled professionals 3.4 Opportunities 3.4.1 Emerging countries to offer lucrative growth opportunities 3.4.2 Growing adoption of label-free cell-based assays 3.5 Trends 3.5.1 3D cell cultures 3.5.2 Microplate readers for cell-based assays 3.6 Cell-Based Assays Market by Products Type: Forecasts 2018-2028 3.6.1 Instrument Segment Forecasts 2018-2028 3.6.1.1 Equipment Needed to Conduct Cell-Based Assays 3.6.2 Consumables Forecasts 2018-2028 3.6.2.1 Reagents Forecasts 2018-2028 3.6.2.2 Assay kits Forecasts 2018-2028 3.6.2.3 Microplates Forecasts 2018-2028 3.6.2.4 Cell lines Forecasts 2018-2028 3.6.2.5 Probes and labels Forecasts 2018-2028 3.6.3 Software Forecasts 2018-2028 3.6.4 Services Forecasts 2018-2028 3.7 Cell-Based Assays Market by Application: Forecasts 2018-2028 3.7.1 Drug Discovery Forecasts 2018-2028 3.7.2 Basic Research Forecasts 2018-2028 3.7.3 Predictive Technology Forecasts 2018-2028 3.8 Cell-based Assays Market by End-User: Forecasts 2018-2028 3.8.1 Pharma & Biotech Companies Forecasts 2018-2028 3.8.2 Academic Institutions Forecasts 2018-2028 3.8.3 Contract Research Organizations (CROs) Forecasts 2018-2028
4. Leading National Markets for Cell-Based Assays, 2018-2028 4.1 Regional Breakdown of the Global Cell-Based Assays Market, 2018-2028 4.2 Global Cell-Based Assays market: Regional Forecast 2017-2028 4.3 The US Cell-Based Assays Revenue Forecast 2018-2028 4.4 European Union (EU) Cell-Based Assays Market 2018-2028 4.4.1 IMI’s Pan-European Drug Discovery Platform holds Much Promise 4.4.2 EU National Market Share Breakdown, 2017, 2023 and 2028 4.4.3 EU Market: Main National Forecasts, 2018-2028 4.4.4 German Cell-Based Assay Revenue Forecast, 2018-2028 4.4.5 French Cell-Based Assays Revenue Forecast, 2018-2028 4.4.6 UK Cell-Based Assays Revenue Forecast, 2018-2028 4.4.7 Spanish Cell-Based Assays Revenue Forecast, 2018-2028 4.4.8 Italian Cell-Based Assays Revenue Forecast, 2018-2028 4.5 Japanese Cell-Based Assays Revenue Forecast, 2018-2028 4.6 BRIC Nations (Brazil, Russia, India and China) Cell-Based Assays Market 4.6.1 BRIC Countries National Breakdown, 2017, 2023 and 2028 4.6.2 BRIC Countries National Forecasts, 2018-2028 4.6.3 Chinese Cell-Based assay Revenue Forecast, 2018-2028 4.6.4 Indian Cell-Based Assays Revenue Forecast, 2018-2028 4.6.5 Russian Cell-Based Assays Revenue Forecast, 2018-2028 4.6.6 Brazilian Cell-Based Assays Revenue Forecast, 2018-2028
5. Leading Companies in the Cell-Based Assays Market, 2017 5.1 DiscoverX Corporation (Eurofins) 5.1.1 Business Overview 5.1.2 Company Snapshot 5.1.3 DiscoverX: Cell-based Assay Product Portfolio 5.1.4 DiscoverX: Financial Overview 5.1.5 DiscoverX: Recent Developments 5.2 Thermo Fisher Scientific 5.2.1 Business Overview 5.2.2 Company Snapshot 5.2.3 Thermo Fisher Scientific: Cell-based Assay Product Portfolio 5.2.4 Thermo Fisher Scientific: Financial Overview 5.2.5 Thermo Fisher Scientific: Recent Developments 5.3 Cell Assay Innovations, Inc. 5.3.1 Business Overview 5.3.2 Company Snapshot 5.3.3 Cell Assay Innovations: Cell-based Assay Product Portfolio 5.3.4 Cell Assay Innovations: Recent Developments 5.4 InSphero AG 5.4.1 Business Overview 5.4.2 Company Snapshot 5.4.3 InSphero AG: Cell-based Assay Product Portfolio 5.4.4 InSphero AG: Recent Developments 5.5 QGel SA. 5.5.1 Business Overview 5.5.2 Company Snapshot 5.5.3 QGel SA.: Cell-based Assay Product Portfolio 5.5.4 QGel SA.: Recent Developments 5.6 Becton, Dickinson and Company 5.6.1 Business Overview 5.6.2 Company Snapshot 5.6.3 BD.: Cell-based Assay Product Portfolio 5.6.4 BD: Financial Overview 5.6.5 BD: Recent Developments 5.7 Promega Corporation 5.7.1 Business Overview 5.7.2 Company Snapshot 5.7.3 Promega: Cell-based Assay Product Portfolio 5.7.4 Promega Corporation: Recent Developments 5.8 BioVision, Inc. 5.8.1 Business Overview 5.8.2 Company Snapshot 5.8.3 BioVision, Inc.: Cell-based Assay Product Portfolio 5.8.4 BioVision, Inc.: Recent Developments 5.9 Marin Biologic Laboratories 5.9.1 Business Overview 5.9.2 Company Snapshot 5.9.3 Marin Biologic: Cell-based Assay Product Portfolio 5.10 Molecular Devices, LLC. (Danaher Corporation) 5.10.1 Business Overview 5.10.2 Company Snapshot 5.10.3 Molecular Devices, LLC: Cell-based Assay Product Portfolio 5.10.4 Danaher Corporation: Financial Overview 5.10.5 Molecular Devices, LLC.: Recent Developments 5.11 Porsolt 5.11.1 Business Overview 5.11.2 Company Snapshot 5.11.3 Porsolt: Cell-based Assay Product Portfolio 5.11.4 Porsolt: Recent Developments 5.12 CYTOO SA 5.12.1 Business Overview 5.12.2 Company Snapshot 5.12.3 CYTOO SA: Cell-based Assay Product Portfolio 5.12.4 CYTOO SA: Recent Developments 5.13 Pharmaceutical Product Development, LLC. 5.13.1 Business Overview 5.13.2 Company Snapshot 5.13.3 Pharmaceutical Product Development, LLC: Cell-based Assay Product Portfolio 5.13.4 Pharmaceutical Product Development, LLC.: Recent Developments 5.14 ProQinase GmbH 5.14.1 Business Overview 5.14.2 Company Snapshot 5.14.3 ProQinase GmbH: Cell-based Assay Product Portfolio 5.15 Charles River Laboratories International, Inc. 5.15.1 Business Overview 5.15.2 Company Snapshot 5.15.3 Charles River Laboratories International, Inc.: Cell-based Assay Product Portfolio 5.15.4 Charles River Laboratories International, Inc.: Financial Overview 5.15.5 Charles River Laboratories: Recent Developments 5.16 BioAgilytix Labs 5.16.1 Business Overview 5.16.2 Company Snapshot 5.16.3 BioAgilytix Labs: Cell-based Assay Product Portfolio 5.16.4 BioAgilytix Labs: Recent Developments 5.17 SGS Group 5.17.1 Business Overview 5.17.2 Company Snapshot 5.17.3 SGS Group: Cell-based Assay Product Portfolio 5.17.4 SGS Group, Inc.: Financial Overview 5.17.5 SGS Group: Recent Developments 5.18 Perkin Elmer Inc. 5.18.1 Business Overview 5.18.2 Company Snapshot 5.18.3 Perkin Elmer: Cell-based Assay Product Portfolio 5.18.4 Perkin Elmer: Financial Overview 5.18.5 Perkin Elmer: Recent Developments 5.19 General Electric Company (GE Healthcare) 5.19.1 Business Overview 5.19.2 Company Snapshot 5.19.3 General Electric Company.: Cell-based Assay Product Portfolio 5.19.4 General Electric Company: Financial Overview 5.19.5 General Electric Company: Recent Developments
6. Cell-Based Assays Technology, Trends and Future Outlook 6.1 Stem Cells: Vast Potential 6.1.1 The Benefits of Using Stem Cells in Cell-Based Assays 6.1.2 iPSCs: An Uncontroversial and Abundant Source 6.1.3 Companies Providing Stem Cell-Based Assays 6.2 Toxicity Testing: Important Field for Cell-Based Assays 6.3 3D Systems: The Advantages of Next Generation of Cell Systems 6.3.1 Complexity of 3D Systems is a Challenge but More are Reaching the Market 6.3.2 Organoids – The Future of Drug Development 6.3.2.1 Hurdles to the Future Organoid Market 6.3.2.2 Organoids Now and in the Future 6.3.3 Bio-Printing for Drug Development: Using 3D Printing Technology 6.4 Increasing Outsourcing of Cell-Based Assays 6.5 Label-Free Technology 6.6 GPCRs: A Common Drug and Drug Discovery Target 6.6.1 GPCRs in Cell-Based Assays 6.6.2 Allosteric GPCRs 6.7 Increasing Miniaturisation and Automation 6.7.1 Advantages of Miniaturisation 6.7.2 Advantages of Automation 6.8 Microfluids are Set to be a Trend 6.8.1 The Potential Challenges to Microfluids 6.9 Multiplexing: Improves Efficiency of cell-Based Assays 6.9.1 Advantages will Drive Growth 6.10 High Content Screening: A Well-Established Tool 6.10.1 The Future for HCS: Will Continue to Expand, Still Room for Innovation 6.11 Cell-Based Assays for the Development of Biologics
7. Qualitative Analysis of the Cell-Based Assays Market, 2017 7.1 SWOT Analysis of the Cell-Based Assays Market 7.1.1 Strengths Within the Cell-Based Assay Market 7.1.2 Weaknesses Within the Cell-Based Assays Market 7.1.3 Opportunities for the Cell-Based Assays Market 7.1.4 Threats to the Cell-Based Assays Market 7.2 STEP Analysis of the Cell-Based Assays Market 7.2.1 Social Factors 7.2.2 Technological Factors 7.2.3 Economic Factors 7.2.4 Political Factors
8. Conclusions from the Research and Analysis 8.1 Growth Has Been Driven by Advantages of Cell-Based Assays 8.2 Current Status of the Market and its Growth Drivers 8.3 The Most Dominant National Markets and Emerging Countries 8.4 Future Trends and Technology
Appendices Associated Reports Visiongain Report Sales Order Form About Visiongain Report Evaluation Form
List of Figures Figure 1.1 Cell-Based Assays Market Segmented by Application Figure 1.2 Cell-Based Assays Market Segmented by Product Figure 1.2 Cell-Based Assays Market Segmented by End-User Figure 2.1 Stages of Pre-Clinical Drug Development Figure 3.1 Global Cell-Based Assays Market Forecast: Revenue ($m), 2017-2028 Figure 3.2 Estimated number of new lung cancer cases worldwide, 2012-2025 Figure 3.3 Estimated number of new pancreatic cancer cases worldwide, 2012-2025 Figure 3.4 R&D investment of phRMA members between 2011 and 2015 Figure 3.5 Drivers and Restraints for the Cell-Based Assays Market, 2018 Figure 3.6 Cell-Based Assays Market Segments Forecasts: Revenue ($m), 2017-2028 Figure 3.7 Cell-Based Assays Market Segments: Instruments Forecast - Revenue ($m), 2017-2028 Figure 3.8 Cell-Based Assays Market Segments: Instruments Forecast -AGR (%), 2017-2028 Figure 3.9 Cell-Based Assays Market Segments: Consumables Forecast - Revenue ($m), 2017-2028 Figure 3.10 Cell-Based Assays Market Segments: Consumables Forecast -AGR (%), 2017-2028 Figure 3.11 Cell-Based Assays Market Segments: Reagents Forecast -AGR (%), 2017-2028 Figure 3.12 Cell-Based Assays Market Segments: Reagents Forecast -AGR (%), 2017-2028 Figure 3.13 Cell-Based Assays Market Segments: Assay Kits Forecast - Revenue ($m), 2017-2028 Figure 3.14 Cell-Based Assays Market Segments: Assay Kits Forecast -AGR (%), 2017-2028 Figure 3.15 Cell-Based Assays Market Segments: Microplates Forecast - Revenue ($m), 2017-2028 Figure 3.16 Cell-Based Assays Market Segments: Microplates Forecast -AGR (%), 2017-2028 Figure 3.17 Cell-Based Assays Market Segments: Cell Lines Forecast - Revenue ($m), 2017-2028 Figure 3.18 Cell-Based Assays Market Segments: Cell Lines Forecast -AGR (%), 2017-2028 Figure 3.19 Cell-Based Assays Market Segments: Probes and Labels Forecast - Revenue ($m), 2017-2028 Figure 3.20 Cell-Based Assays Market Segments: Probes and Labels Forecast -AGR (%), 2017-2028 Figure 3.21 Cell-Based Assays Market Segments: Software Forecast - Revenue ($m), 2017-2028 Figure 3.22 Cell-Based Assays Market Segments: Software Forecast -AGR (%), 2017-2028 Figure 3.23 Cell-Based Assays Market Segments: Services Forecast - Revenue ($m), 2017-2028 Figure 3.24 Cell-Based Assays Market Segments: Services Forecast –AGR (%), 2017-2028 Figure 3.25 Cell-Based Assays Market Application Forecasts: Revenue ($m), 2017-2028 Figure 3.26 Drug Discovery Segment Forecast: Revenue ($m), 2017-2028 Figure 3.27 Drug Discovery Segment Forecast: AGR (%), 2017-2028 Figure 3.28 Basic Research Segment Forecast: Revenue ($m), 2017-2028 Figure 3.29 Basic Research Segment Forecast: AGR (%), 2017-2028 Figure 3.30 Predictive Technology Segment Forecast: Revenue ($m), 2017-2028 Figure 3.31 Predictive Technology Segment Forecast: AGR (%), 2017-2028 Figure 3.32 Cell-Based Assays Market End Users Forecasts: Revenue ($m), 2017-2028 Figure 3.33 Pharma & Biotech Companies Forecast: Revenue ($m), 2017-2028 Figure 3.34 Pharma & Biotech Companies Forecast: AGR (%), 2017-2028 Figure 3.35 Academic Institutes Forecast: Revenue ($m), 2017-2028 Figure 3.36 Academic Institutes Forecast: AGR (%), 2017-2028 Figure 3.37 CROs Forecast: Revenue ($m), 2017-2028 Figure 3.38 CROs Forecast: AGR (%), 2017-2028 Figure 4.1 Cell-Based Assays Market Breakdown by Region: Market Shares (%), 2017 Figure 4.2 Cell-Based Assays Market Breakdown by Region: Market Shares (%), 2023 Figure 4.3 Cell-Based Assays Market Breakdown by Region: Market Shares (%), 2028 Figure 4.4 Global Cell-Based Assays Market Regional Forecasts: Revenues ($m), 2017-2028 Figure 4.5 US Cell-Based Assays Market Forecast: Revenues ($m), 2017-2028 Figure 4.6 US Cell-Based Assays Market Forecast: AGR (%), 2017-2028 Figure 4.7 EU Cell-Based Assays Market Forecast: Revenues ($m), 2017-2028 Figure 4.8 EU Cell-Based Assays Market Forecast: AGR (%), 2017-2028 Figure 4.9 EU Market Breakdown by Nation: EU Market Shares (%), 2017 Figure 4.10 EU Market Breakdown by Nation: Market Shares (%), 2023 Figure 4.11 EU Market Breakdown by Nation: Market Shares (%), 2028 Figure 4.12 EU Market, Top National Forecasts: Revenue ($m), 2017-2028 Figure 4.13 German Cell-Based Assays Market Forecast: Revenues ($m), 2017-2028 Figure 4.14 German Cell-Based Assays Market Forecast: AGR (%), 2017-2028 Figure 4.15 French Cell-Based Assays Market Forecast: Revenues ($m), 2017-2028 Figure 4.16 French Cell-Based Assays Market Forecast: AGR (%), 2017-2028 Figure 4.17 UK Cell-Based Assays Market Forecast: Revenues ($m), 2017-2028 Figure 4.18 UK Cell-Based Assays Market Forecast: AGR (%), 2017-2028 Figure 4.19 Spanish Cell-Based Assays Market Forecast: Revenues($m), 2017-2028 Figure 4.20 Spanish Cell-Based Assays Market Forecast: AGR (%), 2017-2028 Figure 4.21 Italian Cell-Based Assays Market Forecast: Revenues($m), 2017-2028 Figure 4.22 Italian Cell-Based Assays Market Forecast: AGR (%), 2017-2028 Figure 4.23 Japanese Cell-Based Assays Market Forecast: Revenues($m), 2017-2028 Figure 4.24 Japanese Cell-Based Assays Market Forecast: AGR (%), 2017-2028 Figure 4.25 BRIC Countries Breakdown by Nation: Market Shares (%), 2017 Figure 4.26 BRIC Countries Breakdown by Nation: Market Shares (%), 2023 Figure 4.27 BRIC Countries Breakdown by Nation: Market Shares (%), 2028 Figure 4.28 BRIC Countries Breakdown by Nation: Revenues ($m), 2017-2028 Figure 4.29 Chinese Cell-Based Assays Market Forecast: Revenues ($m), 2017-2028 Figure 4.30 Chinese Cell-Based Assays Market Forecast: AGR (%), 2017-2028 Figure 4.31 Indian Cell-Based Assays Market Forecast: Revenues ($m), 2017-2028 Figure 4.32 Indian Cell-Based Assays Market Forecast: AGR (%), 2017-2028 Figure 4.33 Russian Cell-Based Assays Market Forecast: Revenues ($m), 2017-2028 Figure 4.34 Russian Cell-Based Assays Market Forecast: AGR (%), 2017-2028 Figure 4.35 Brazilian Cell-Based Assays Market Forecast: Revenue ($m), 2017-2028 Figure 4.36 Brazilian Cell-Based Assays Market Forecast: AGR (%), 2017-2028 Figure 5.1 Thermo Fisher Scientific: Net Revenues, 2015-2017 ($Million) Figure 5.2 Thermo Fisher Scientific: Net Revenue by Segment, 2017 Figure 5.3 Thermo Fisher Scientific: Net Revenue by Geography, 2017 Figure 5.4 BD: Net Revenues, 2015-2017 ($Million) Figure 5.5 BD: Net Revenue by Segment, 2017 Figure 5.6 BD: Net Revenue by Geography, 2017 Figure 5.7 Danaher Corporation: Net Revenues, 2015-2017 ($Million) Figure 5.8 Danaher Corporation: Net Revenue by Segment, 2017 Figure 5.9. Danaher Corporation: Net Revenue by Geography, 2017 Figure 5.10 Charles River Laboratories: Net Revenues, 2015-2017 ($Million) Figure 5.11 Charles River Laboratories: Net Revenue by Segment, 2017 Figure 5.12 Charles River Laboratories: Net Revenue by Geography, 2017 Figure 5.13 SGS Group: Net Revenues, 2015-2017 ($Million) Figure 5.14 SGS Group: Net Revenue by Segment, 2017 Figure 5.15 SGS Group: Net Revenue by Geography, 2017 Figure 5.16 Perkin Elmer Inc.: Net Revenues, 2015-2017 ($Million) Figure 5.17 Perkin Elmer: Segment Revenues, 2015-2017 ($Million) Figure 5.18 General Electric Company: Net Revenues, 2015-2017 ($Million) Figure 5.19 General Electric Company: Net Revenue by Segment, 2017 Figure 5.20 General Electric Company: Net Revenue by Geography, 2017 Figure 7.1 Strengths and Weaknesses of the Cell-Based Assay Market, 2017 Figure 7.2 Strengths and Weaknesses of the Cell-Based Assay Market, 2017 Figure 8.1 The Cell-Based Assay Submarket Revenue ($m) Breakdown by Products, 2017, 2023 and 2028 Figure 8.2 The Cell-Based Assay Submarket Revenue ($m) Breakdown by Application: Drug Discovery, Basic Research, and Predictive Technology 2017, 2023 and 2028 Figure 8.3 Regional Breakdown of the Cell-based Assay Market by Revenue ($m), 2017, 2023 and 2028
Abcam Accuri Cytometers, Inc. Affymetrix, Inc. Agilent Technologies Applied Biosystems Ascendance Biotechnology AstraZeneca ATCC AXAM Axiogenesis AG B’SYS GmbH BASF Bayer Becton, Dickinson and Company Becton Dickinson Asia Limited Becton Dickinson Biosciences BioAgilytix Labs BioCity Biocroi Biofungitek BioIVT Biotechnology Industry Research Assistance Council (BIRAC) BioVision, Inc. BMG LABTECH GmbH C.R. Bard Caliper Life Sciences, Inc. Cambridge Research & Instrumentation, Inc. Cell Assay Innovations (CAI) Cell Biolabs Charles River Germany GmbH & Co. KG Charles River Holdings LLC Charles River Laboratories Charles River Laboratories International, Inc. Charles River Laboratories, Inc. Charles River Nederland BV Charles River UK Limited Cisbio Bioassays Cohesive Technologies Inc. Contextual Genomics CYTOO SA Daiichi Sankyo Company Limited Danaher Corporation Department of Biotechnology (DBT) DiscoverX Dr. Reddy’s Laboratories Draconis Pharma Eurofins Scientific S.E. EUROIMMUN US Inc. Food and Drug Administration (FDA) Fisher Scientific FLUOFARMA Foundation Top Institute Pharma Fulcrum Therapeutics GE Healthcare GE Healthcare AS GE Healthcare Bio-Sciences AB GE Healthcare BVBA GE Healthcare European Holdings SARL GE Healthcare Japan Corporation GE Healthcare USA Holding LLC General Electric Company GIMDx, Inc. Guangzhou Improve Medical Instruments HD Biosciences Co., Ltd. Helsinki Institute of Life Science Icagen, Inc. Idengene SA IncellDx, Inc Indian Institute of Chemical Technology (IICT) Innoprot InSphero AG IntelliCyt Interchim Invitrogen Janssen Jubilant Biosys Labcyte Inc. Lead Discovery Centre GmbH Likarda Luxcel Biosciences Ltd Marin Biologic Laboratories Mayflower Biosciences Merck KGaA Metrion Biosciences Ltd Molecular Devices, LLC NanoString Technologies, Inc. Ncardia NEOMED Institute Netherlands Cancer Institute Neuron BioServices NovaScreen Biosciences Corporation NovaWave Technologies, Inc. On Target Co., Ltd Oncotest Pelago Bioscience Perkin Elmer Inc. Phadia GmbH Pharmaceutical Product Development (PPD) Pharmaceutical Product Development, LLC. Phenomics Discovery Initiative (PDi) Pluriomics B.V. Porsolt Porsolt and Fluofarma acquisition Premas Lifescience Promega Corporation ProQinase GmbH QGel SA. Riken Genesis Russian Federation Sanofi Science Exchange SGS Australia SGS Belgium NV SGS Central America S.A. SGS Group SGS North America Inc. Skolkovo Foundation StemTek therapeutics Sygnature Discovery Syncom Sysmex Corporation Systems and Reagents Inc. Takeda Pharmaceutical Company Limited Tecan Group Ltd. The Structural Genomics Consortium Thermo Electron A/S Thermo Fisher Scientific (and Affymetrix acquisition) Thermo Fisher Scientific Operating Company LLC Thermo Fisher Scientific Senior Financing LLC Thermo Scientific Tufts Center for the Study of Drug Development UCB Unity Lab Services Valneva SE VitoTag Biosciences Xenogen Corporation ZF BioLabs ZF Biotox
List of Organisations mentioned in the report All India Institute of Medical Sciences (AIIMS) American Society of Cell Biology (ASCB) AMR Centre (AMRC) Association of Research-Based Pharmaceutical Companies Biotechnology Industry Research Assistance Council (BIRAC) Department of Biotechnology (DBT) Foundation Top Institute Pharma Helsinki Institute of Life Science Imperial College London Indian Institute of Chemical Technology (IICT) Innovative Medicines Initiative (IMI) nstitute for Chemical Sciences in Rennes Institute for In Vitro Sciences, Inc. (IIVS) Institute for Molecular Medicine Finland (FIMM) Karolinska Institutet Medical Research Council (MRC) Centre for Regenerative Medicine (CRM) Memorial Sloan Kettering Cancer Center (MSK) National Health Service (NHS) National Phenotypic Screening Centre (NPSC) NEOMED Institute Netherlands Cancer Institute Oxford University Pharmaceutical Research and Manufacturers of America (PhRMA) Phenomics Discovery Initiative (PDi) Russian Federation Science Exchange Skolkovo Foundation Tufts Center for the Study of Drug Development Unity Lab Services University of Dundee University of Edinburgh University of Helsinki University of Oxford World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for Cell-Based Assays World Industry and Market 2018-2028
The latest report from business intelligence provider visiongain offers comprehensive analysis of the global influenza vaccines market. Visiongain assesses that...
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
